-
Controversial Alzheimer’s Drug Aduhelm Dropped by Drugmaker After Doubtful Data and Denied Coverage -
Hundreds of Drugmakers Call for Reversal of Texas Court Ruling on Abortion Pill
-
VHA to Cover Eisai, Biogen’s Alzheimer’s Drug for Eligible Veterans
-
Biogen Agrees to Pay $900 Million in Drug Kickbacks Settlement, Denies Wrongdoing
-
FDA Finally Approved an Alzheimer’s Drug—But Everything Surrounding It Is Controversial
-
Biogen, Eisai Alzheimer’s Drug Lecanemab Gets ‘Fast Track’ Designation From FDA
-
Biogen Halves Price of Alzheimer’s Drug to $28,200
-
Doctors Weigh Prescribing Controversial Alzheimer’s Drug
-
US Review of Biogen Alzheimer’s Drug Could Have Been Handled Differently: FDA Chief
-
FDA Approves Biogen Alzheimer’s Drug
-
15 New Coronavirus Cases Linked to Biogen Conference in Boston
-
Biogen Scraps Alzheimer Drug Trials, Wiping $17 Billion Off Its Market Value
